KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. PMID 39454735 · Int J Radiat Oncol Biol Phys · 2025-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531. PMID 40150760 · Bioengineering (Basel) · 2025-Mar-14 The record describes a secondary analysis (predictive model development) of data from a Phase III RCT, not the original formal result report of the trial's primary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prospective randomized study of the efficacy of continuous active warming in patients undergoing laparoscopic gastrectomy. PMID 40087578 · BMC Gastroenterol · 2025-Mar-14 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple resection (SPARROW): a study protocol for a multicentre, open-label, randomised controlled trial. PMID 40083036 · Trials · 2025-Mar-13 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The long-term impact of single intraoperative instillation of pirarubicin after radical nephroureterectomy on local and systemic cancer control: a prospective, multicenter, randomized trial. PMID 40080123 · World J Urol · 2025-Mar-13 While the study is oncology, human, randomized, and reports a time-to-event endpoint (OS), the phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. The deterministic review also flagged this uncertainty. Furthermore, the primary efficacy endpoint of the trial is intravesical recurrence (IVR), which is a local recurrence metric. The study reports no significant difference in OS, but OS is presented as a secondary or exploratory outcome, not the primary/key secondary time-to-event efficacy endpoint for which the trial was designed. Therefore, the core eligibility criteria of a Phase III/IIIb or II/III trial with a primary/key secondary time-to-event efficacy endpoint are not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quadratus lumborum block is feasible alternative to epidural block for postoperative analgesia after open radical cystectomy: surgical and oncological outcomes of a randomised clinical trial. PMID 40079670 · Scand J Urol · 2025-Mar-13 The study is excluded because it does not involve a drug-containing intervention and does not report a primary/key time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR analysis. It is a trial of regional anesthesia techniques for postoperative pain management in bladder cancer surgery, focusing on analgesic and complication outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiotherapy quality assurance in the PROTECT trial - a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer. PMID 40079654 · Acta Oncol · 2025-Mar-13 The record describes a quality assurance sub-study within a phase III randomized trial. It does not report a drug intervention or a time-to-event efficacy endpoint, which are required for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. PMID 39665649 · N Engl J Med · 2025-Mar-13 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma. PMID 40072044 · Cancer Biol Med · 2025-Mar-12 The study is eligible for inclusion based on oncology, human subjects, phase 3, time-to-event endpoints, and drug intervention. However, it cannot be marked as eligible because the abstract and metadata do not provide explicit evidence of randomization, which is a required criterion for a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. PMID 40139261 · Oncologist · 2025-Mar-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial. PMID 40088185 · Oncologist · 2025-Mar-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of adapted physical activity and diet counselling on health-related quality of life in women undergoing adjuvant breast cancer therapy. PMID 40064980 · Sci Rep · 2025-Mar-10 The study is a randomized, oncology trial with a drug-containing intervention, but the primary/ key secondary endpoints are health-related quality of life (HRQoL) and its analysis. The survival analysis for time to deterioration of HRQoL is presented as a methodological approach, not as a primary or key secondary efficacy endpoint for drug intervention. Therefore, it lacks the required primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET). PMID 39586038 · J Clin Oncol · 2025-Mar-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dummy run study for outlining and plan quality of intensity-modulated radiotherapy in elderly patients with newly diagnosed glioblastoma: The Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). PMID 40059195 · Radiat Oncol · 2025-Mar-09 The report is a protocol-focused quality assurance study (dummy run) for a phase III trial, not a report of trial efficacy results. It does not contain any time-to-event outcome data and the intervention is not drug-containing.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers and May Improve Outcomes after Large Vessel Occlusion Strokes: Results of the Randomized Clinical Trial NUVISTA. PMID 40093228 · medRxiv · 2025-Mar-07 The trial is not oncology; it is a randomized trial of transcutaneous auricular vagus nerve stimulation (a device/neuromodulation) for ischemic stroke, not a drug intervention, and the primary/secondary endpoints are biomarkers and clinical scores, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. PMID 40055382 · NPJ Breast Cancer · 2025-Mar-07 The study is a secondary biomarker analysis from a Phase III randomized trial in breast cancer, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The endpoint analyzed is pathological complete response (pCR), which is a binary endpoint. Additionally, the specific drug intervention is not described in the abstract. Therefore, it does not meet the inclusion criteria for a drug-intervention Phase III/IIIb trial with a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Oral Intake of Hydrogen-Rich Jelly Intake on Gingival Inflammation: A Double-Blind, Placebo-Controlled and Exploratory Randomized Clinical Trial. PMID 40077138 · Healthcare (Basel) · 2025-Mar-06 The study is a randomized, placebo-controlled trial reporting primary results, but it is not an oncology study, does not involve a drug intervention, and lacks a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Screening to identify people with type 2 diabetes at risk of liver cancer in primary care: a randomised controlled trial protocol. PMID 40050060 · BMJ Open · 2025-Mar-06 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial. PMID 41891861 · BJS Open · 2025-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comprehensive evaluation of tumor response better evaluates the efficacy of neoadjuvant chemotherapy and predicts the prognosis in gastric cancer - a post hoc analysis of a single-center randomized controlled trial. PMID 40045265 · BMC Cancer · 2025-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of peritoneal bladder flap in robot-assisted radical prostatectomy patients on lymphoceles: a prospective randomised trial. PMID 40044802 · World J Urol · 2025-Mar-05 The study is an oncology (prostate cancer), human, randomized, prospective trial with primary results. However, it is excluded because: 1) The intervention is a surgical technique modification (peritoneal flap fixation), not a drug-containing intervention. 2) The primary endpoint is a complication rate (lymphoceles requiring intervention), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR-based endpoint). 3) The study is not Phase III/IIIb or Phase II/III; no phase is specified but it is a definitive randomized trial, but the drug criterion is not met. The report is the primary result of the trial, not a subgroup, safety, or other analysis type.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Hypotension Prediction Index in Free Flap Transplant in Head and Neck Surgery: Protocol of a Prospective Randomized Controlled Trial. PMID 40141745 · Life (Basel) · 2025-Mar-04 The record is a protocol for a randomized trial in oncology patients (head and neck cancer surgery), but it evaluates a monitoring technology (Hypotension Prediction Index) against standard care for intraoperative hypotension, not a drug intervention. The primary endpoint is a hemodynamic measure (time-weighted average MAP), not a time-to-event efficacy outcome like OS/PFS. It is a protocol without reported results, and the trial phase is not specified as definitive (Phase III/IIIb or II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trial. PMID 40042985 · Br J Surg · 2025-Mar-04 The trial meets oncology, human, randomized, time-to-event, and original-result criteria. However, it fails the drug-intervention criterion because the comparison is surgical (axillary surgery vs. no-axillary staging). Furthermore, the trial phase is not confirmed as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers. PMID 40038236 · Cell Death Dis · 2025-Mar-04 The record is a preclinical and retrospective analysis study, not an original formal-result report of a randomized trial. While it references a phase III study, the abstract does not describe the trial's results in terms of time-to-event endpoints (OS, PFS, etc.) or survival analysis methods. It focuses on biomarker analysis (PD-L1, tumor size) and mechanisms of immune checkpoint blockade response.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). PMID 39556015 · Circulation · 2025-Mar-04 The study is a randomized trial in cancer patients evaluating rivaroxaban duration for pulmonary embolism, but it does not meet the core eligibility criteria: it lacks a cancer-specific drug intervention for efficacy (rivaroxaban is an anticoagulant, not an anticancer therapy) and does not have a time-to-event primary efficacy endpoint (OS, PFS, DFS, etc.) as required. The primary endpoint (recurrent VTE) is a safety/thrombotic outcome, not a cancer efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials. PMID 40080017 · JAMA Netw Open · 2025-Mar-03 This is a secondary analysis of healthcare burden in phase 3 randomized oncology trials, not a report of primary/time-to-event efficacy results for a drug intervention.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Somatic acupressure for the management of the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a study protocol for a phase III randomised controlled trial. PMID 40032405 · BMJ Open · 2025-Mar-03 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China. PMID 40032375 · BMJ Open · 2025-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. PMID 39947918 · J Nucl Med · 2025-Mar-03 The record describes a Phase III randomized trial (NETTER-1) but this specific publication is a dosimetry/toxicity substudy. It is not randomized (the substudy itself does not randomize), and the primary efficacy endpoint is not time-to-event (no OS/PFS/DFS/etc. reported; only exploratory tumor size changes and dosimetry results). Therefore, it does not meet the required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer. PMID 39945807 · JNCI Cancer Spectr · 2025-Mar-03 The record is excluded because it is not an original result report of a single Phase III or Phase II/III randomized trial. It is a meta-analytical or observational study that synthesizes results from multiple trials to assess real-world effectiveness, thus failing the 'original_result' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial. PMID 39786436 · Clin Cancer Res · 2025-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors. PMID 40024914 · Cancer Immunol Immunother · 2025-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. PMID 39878970 · JAMA Dermatol · 2025-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial. PMID 39786764 · JAMA Oncol · 2025-Mar-01 The study is a randomized clinical trial with oncology focus and a time-to-event efficacy endpoint (overall survival), but it does not involve a drug-containing intervention; the intervention is a shared care model. Therefore, it does not meet the criterion of a drug-containing intervention required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial. PMID 39745682 · JAMA Oncol · 2025-Mar-01 The study is a Phase III oncology trial with drug intervention and time-to-event endpoints, but it is explicitly described as nonrandomized, which fails a key eligibility criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial. PMID 39506905 · Haematologica · 2025-Mar-01 Cannot confirm Phase III/IIIb or Phase II/III evidence from the provided metadata. The trial is randomized, involves a drug intervention, has a time-to-event endpoint (DFS), and reports original results, but the specific trial phase is not stated in the title, abstract, or publication types. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer. PMID 39357788 · Int J Radiat Oncol Biol Phys · 2025-Mar-01 The study is an original, randomized, phase 3 oncology trial in humans. However, the primary endpoint is patient-reported quality of life (bowel health), and the intervention is radiation therapy (proton therapy vs. IMRT), not a drug-containing intervention. No time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier analysis) is reported or described as primary/key secondary. Therefore, it does not meet all criteria for inclusion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial. PMID 39353477 · Int J Radiat Oncol Biol Phys · 2025-Mar-01 This is a primary report of a Phase III randomized trial in oncology with a drug-containing intervention (chemotherapy), but its primary endpoint is safety/toxicity, not a time-to-event efficacy endpoint (e.g., OS, PFS). The abstract confirms efficacy outcomes are not yet reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery. PMID 39045699 · Ann Surg · 2025-Mar-01 The study is a randomized trial in oncology with time-to-event endpoints, but the intervention is a non-drug perioperative management strategy, not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Sugammadex Versus Neostigmine Reversal on Postoperative Recovery Time in Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial. PMID 38848257 · Anesth Analg · 2025-Mar-01 The study is a randomized controlled trial in human patients with a drug intervention (sugammadex vs neostigmine). However, it is a non-oncology study focusing on postoperative recovery in bariatric surgery patients with obstructive sleep apnea, and its primary and secondary endpoints are not time-to-event efficacy outcomes (OS, PFS, DFS, etc.) but rather recovery time metrics (OR discharge time, eye opening time, extubation time).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). PMID 40221173 · Gynecol Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Single-dose vs prolonged antibiotic prophylaxis of fosfomycin for transrectal prostate biopsy: a single-center prospective, randomized, controlled trial. PMID 40213351 · Prostate Int · 2025-Mar The study is a randomized controlled trial evaluating antibiotic prophylaxis for prostate biopsy, not a treatment trial for human malignant neoplasm. While it involves a drug and reports original results, it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) and is not in the context of cancer treatment.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-inflammatory potential of royal jelly in multiple sclerosis disease: a double randomized clinical trial. PMID 40213172 · Ann Med Surg (Lond) · 2025-Mar The study is a randomized clinical trial in humans with original results, but it is not an oncology study, the intervention is not a drug, and the primary endpoints are not time-to-event efficacy measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison between opioid-based anaesthesia technique and opioid-free anaesthesia technique in patients undergoing laparotomy for gynaecological malignancy: A randomised controlled trial. PMID 40161920 · Indian J Anaesth · 2025-Mar Eligibility requires an explicit time-to-event efficacy endpoint (e.g., OS, PFS) for a drug intervention in a Phase III/IIIb or Phase II/III randomized trial. This study is a randomized trial in oncology patients but evaluates perioperative anesthetic techniques, not a systemic drug's efficacy on cancer survival or progression endpoints. It lacks the required time-to-event outcome and definitive phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: 5-year results of the CAO/ARO/AIO-12 trial - a general pairwise comparison. PMID 40056849 · ESMO Open · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preoperative Platelet-Rich Plasma Injections Decrease Inflammatory and Chondrodegenerative Biomarkers in Patients With Acute Anterior Cruciate Ligament Tears: A Pilot Randomized Controlled Trial. PMID 40052182 · Orthop J Sports Med · 2025-Mar The record describes a randomized pilot trial evaluating platelet-rich plasma (PRP) injections for acute anterior cruciate ligament tears, measuring inflammatory and chondrodegenerative biomarkers. It is non-oncology, uses a non-drug-only intervention (PRP), and does not report a time-to-event efficacy endpoint (like OS, PFS, etc.) or Kaplan-Meier/HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. PMID 40049198 · Lancet Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. PMID 40049196 · Lancet Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. PMID 40034001 · J Neuromuscul Dis · 2025-Mar 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions. PMID 40033991 · J Neuromuscul Dis · 2025-Mar 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -